Compare Organon & Co. Common Stock (OGN) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Consumer Discretionary Select Sector SPDR Fund trades at $111.34 (market cap $21.98B). The key difference: Consumer Discretionary Select Sector SPDR Fund is far larger — about 6.1× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Consumer Discretionary Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Consumer Discretionary Select Sector SPDR Fund for 115 Days on average.
| OGN | XLY | |
|---|---|---|
Market Cap | $3.62B | $21.98B |
Volume | 2,892,999 | 5,684,050 |
Sector | Health | — |
52-Week High | $13.81 | $124.52 |
52-Week Low | $5.70 | $105.64 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
XLY trades at $112.36 with minimal daily movement (+0.07%), showing technical indecision with a bullish overall signal but bearish moving averages. The ETF has underperformed the broader market in 2026, declining over 7% while consumer staples gained 6.6%. Analyst consensus remains unanimously bullish with a 100% buy rating, though recent news highlights persistent underperformance concerns and consumer spending shifts toward value.
The outlook remains mixed with technical indicators suggesting potential resistance near $113 while fundamental exposure to consumer discretionary spending faces inflation pressures. Key risks include continued market underperformance and consumer sensitivity to economic conditions, though potential catalysts exist from holiday retail growth projections and cyclical sector opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
